Leadership & Founders
Board of Directors
Scientific Advisory Board
KARMET- Phase 2b
RASMET – Phase 2a
Enterin is aiming to become the first company
in the world to develop a novel drug that
repairs the dysfunctional
in patients with neurodegenerative disease.
In preclinical model of Parkinson’s Disease,
our lead compound displaces α-synuclein aggregates
and restores normal signaling between the gut and the brain.
In December 2018,
we initiated a Phase 2B study of ENT-01
in patients with Parkinson's Disease.
We hope that repair of the gut-brain axis is able to
quality of life
by influencing multiple non-motor symptoms that affect patients with Parkinson’s Disease and other neurodegenerative conditions.
Watch an interview with one of Enterin’s founders,
Dr. Michael Zasloff, discussing a new hope
autism and other neurodegenerative diseases.
WATCH THE VIDEO